In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor.

A new study from Memorial Sloan Kettering Cancer Center finds that in colorectal cancer, not all regulatory T cells are created equal. One subtype suppresses cancer growth while another aids it. The ...

Rucaparib maintenance therapy provided consistent benefits across all subgroups of patients grouped by prognostic factors of their homologous recombination deficiency-negative ovarian cancer tumors.